Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effects of VX-264 for Patients with Type 1 Diabetes

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for Type 1 Diabetes, a condition where the body cannot produce insulin, a hormone needed to control blood sugar levels. The treatment being tested is called the VX-264 Implant, which is a type of cell therapy. This implant is designed to help the body manage blood sugar levels by using a special device called the human channel array device (HCAD). The HCAD is an implantable device that protects the cells from being attacked by the immune system and helps them receive nutrients and oxygen.

The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the VX-264 Implant in people with Type 1 Diabetes. Participants in the study will receive the implant, and researchers will monitor how well it works and how the body responds to it. The study will be conducted in different parts, with each part focusing on different aspects of the treatment, such as safety and how well it helps the body produce insulin.

Throughout the study, participants will undergo various assessments to ensure their safety and to measure the treatment's effects. These assessments may include checking vital signs, conducting imaging tests like MRI or ultrasound, and evaluating blood sugar levels. The study aims to provide valuable information about the potential of the VX-264 Implant as a treatment option for people with Type 1 Diabetes.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be informed about the trial's purpose, procedures, and potential risks and benefits.

    Eligibility criteria include being between 18 and 65 years old, having a specific range of HbA1c levels, and a history of Type 1 Diabetes Mellitus (T1D) with insulin dependence for at least 5 years.

  2. Step 2

    Implantation of VX-264

    The participant will receive the VX-264 Implant, which is administered through a procedure called implantation.

    This step involves placing the VX-264 units into the body, which is designed to help manage Type 1 Diabetes.

  3. Step 3

    Monitoring and assessments

    Participants will undergo regular monitoring to evaluate the safety and tolerability of the VX-264 Implant.

    Assessments include clinical laboratory tests, vital signs checks, and imaging assessments such as ultrasound and magnetic resonance imaging.

  4. Step 4

    Evaluation of VX-264 function

    The function of the VX-264 Implant will be evaluated through various tests, including measuring changes in C-peptide levels during a meal test.

    The goal is to assess how well the implant is working in managing blood sugar levels.

  5. Step 5

    Follow-up and data collection

    Participants will continue to be monitored over time to collect data on the implant's effectiveness and any changes in insulin requirements.

    The study aims to observe changes in metabolic control, including HbA1c values and glucose monitoring results.

  6. Step 6

    Completion of the study

    The study is expected to conclude by March 30, 2027.

    Participants will have a final assessment to evaluate the long-term effects and outcomes of the VX-264 Implant.

Who can join the trial?

5 criteria

  • Participants must be between 18 and 65 years old, including both ages, at the time they first agree to join the study.
  • Participants should have a blood test result called **HbA1c** between 6.0% and 9.5%. This test shows the average blood sugar level over the past 2 to 3 months.
  • Participants need to have a history and lab results confirming **Type 1 Diabetes (T1D)**. This includes needing insulin for at least 5 years and having a low level of a substance called **C-peptide** during a special test called **MMTT**.
  • Participants must have been using a **Continuous Glucose Monitor (CGM)** for at least 4 weeks before the study starts and agree to use only the CGM provided by the study during the entire study period.
  • Participants should have a body size that can support the placement of the planned number of study devices called **VX-264 units**.

Who cannot join the trial?

8 criteria

  • Patients who have a different type of diabetes other than Type 1 Diabetes cannot participate. Type 1 Diabetes is a condition where the body does not produce insulin, a hormone needed to control blood sugar levels.
  • Patients who are not within the specified age range for the study cannot participate. The study is open to certain age groups only.
  • Patients who are not willing or able to follow the study procedures cannot participate. This means they must be able to attend all required visits and follow instructions given by the study team.
  • Patients who have any other medical conditions that might interfere with the study cannot participate. This includes conditions that could affect the safety or results of the study.
  • Patients who are pregnant or planning to become pregnant during the study cannot participate. This is to ensure the safety of both the mother and the unborn child.
  • Patients who are currently participating in another clinical trial cannot participate. This is to avoid any interference with the results of either study.
  • Patients who have a history of allergic reactions to any of the study medications cannot participate. This is to prevent any potential allergic reactions during the study.
  • Patients who have a history of substance abuse or alcohol abuse cannot participate. This is to ensure that the study results are not affected by these factors.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

VX-264 is an investigational medication being studied for its potential to help people with Type 1 Diabetes Mellitus. The trial aims to assess how safe and tolerable this medication is for patients, as well as how well it functions in managing the condition. The study is divided into different parts to evaluate these aspects thoroughly.

What is already known about the treatment

VX-264 – VX-264 is administered as an injection and is currently being studied in clinical trials for its safety, tolerability, and effectiveness in treating Type 1 Diabetes Mellitus. It is in the early stages of research, specifically in Phase 1/2 trials, and is not yet widely available in medical practice. The main therapeutic indication for VX-264 is to help manage Type 1 Diabetes by potentially improving insulin production or function. At the molecular level, VX-264 is believed to work by interacting with specific cellular pathways to enhance the body's ability to regulate blood sugar levels. It falls under the pharmacological classification of investigational drugs for diabetes treatment.

Investigated diseases

Type 1 Diabetes Mellitus – Type 1 Diabetes Mellitus is a chronic condition where the pancreas produces little or no insulin, a hormone needed to allow sugar (glucose) to enter cells to produce energy. It typically appears in adolescence or early adulthood but can develop at any age. The disease progresses as the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. This leads to high blood sugar levels, which can cause various symptoms such as increased thirst, frequent urination, hunger, fatigue, and blurred vision. Over time, if not managed properly, it can lead to complications affecting the heart, blood vessels, nerves, eyes, and kidneys. Regular monitoring of blood sugar levels and lifestyle adjustments are crucial for managing this condition.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-515583-32-00Protocol codeVX22-264-101Estimated enrolment17 patientsSponsorVertex Pharmaceuticals Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).